Search

  • HOME
  • Search
Review
1997
Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease
Andrea Caddeo, Stefano Romeo
Clin Mol Hepatol. 2025;31(Suppl):S76-S93.   Published online August 5, 2024
View: 2955   Download: 426  Crossref: 7
Correspondence
The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
Clin Mol Hepatol. 2025;31(2):e183-e185.   Published online February 17, 2025
View: 374   Download: 10  Crossref: 1
Letter to the Editor
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
View: 1074   Download: 65  Web of Science: 1  Crossref: 1
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang
Clin Mol Hepatol. 2025;31(1):e25-e26.   Published online December 10, 2024
View: 849   Download: 38  Crossref: 1
Original Article
2066
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, Silvia Inés García, Adrian Salatino, Silvia Sookoian
Clin Mol Hepatol. 2025;31(1):179-195.   Published online October 11, 2024
View: 1676   Download: 156  Crossref: 1
Review
2076
Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim
Clin Mol Hepatol. 2025;31(1):74-89.   Published online October 23, 2024
View: 3407   Download: 360  Web of Science: 7  Crossref: 10
Original Article
1983
Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis
Ji Won Han, Hee Yeon Kim, Jung Hwan Yu, Mi Na Kim, Young Eun Chon, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Han Ah Lee, Dae Won Jun
Clin Mol Hepatol. 2024;30(Suppl):S147-S158.   Published online July 25, 2024
View: 2307   Download: 137  Web of Science: 4  Crossref: 5
Correspondence
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”
Vy H. Nguyen, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(4):1000-1001.   Published online August 5, 2024
View: 1161   Download: 39
Correspondence
In response to: Steatotic liver disease-know your enemies
Michael H. Le, Linda Henry, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):284-286.   Published online February 19, 2024
View: 2521   Download: 48
Original Article
1881
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2024;30(2):235-246.   Published online January 26, 2024
View: 7549   Download: 314  Web of Science: 22  Crossref: 29
Letter to the Editor
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
Clin Mol Hepatol. 2024;30(1):118-120.   Published online November 14, 2023
View: 2918   Download: 64  Web of Science: 2  Crossref: 1
Review
1759
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol. 2023;29(Suppl):S286-S301.   Published online December 28, 2022
View: 8086   Download: 283  Web of Science: 23  Crossref: 31
1754
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
Anja Geerts, Sander Lefere
Clin Mol Hepatol. 2023;29(Suppl):S276-S285.   Published online December 22, 2022
View: 5144   Download: 156  Web of Science: 10  Crossref: 12
1749
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clin Mol Hepatol. 2023;29(Suppl):S244-S260.   Published online December 14, 2022
View: 8300   Download: 360  Web of Science: 19  Crossref: 22
1728
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clin Mol Hepatol. 2023;29(Suppl):S157-S170.   Published online November 22, 2022
View: 6101   Download: 348  Web of Science: 28  Crossref: 28
1737
Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(Suppl):S103-S122.   Published online November 30, 2022
View: 6700   Download: 274  Web of Science: 23  Crossref: 21
1740
Interaction between sarcopenia and nonalcoholic fatty liver disease
Sae Kyung Joo, Won Kim
Clin Mol Hepatol. 2023;29(Suppl):S68-S78.   Published online December 5, 2022
View: 7394   Download: 338  Web of Science: 38  Crossref: 38
1735
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31.   Published online November 29, 2022
View: 24859   Download: 1,456  Web of Science: 189  Crossref: 204
Letter to the Editor
Letter regarding “Risk factors in nonalcoholic fatty liver disease”
Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh
Clin Mol Hepatol. 2023;29(4):1046-1047.   Published online August 22, 2023
View: 2620   Download: 52  Web of Science: 1  Crossref: 1
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(3):690-692.   Published online May 30, 2023
View: 3079   Download: 111  Web of Science: 2  Crossref: 2
Original Article
1771
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):453-464.   Published online February 1, 2023
View: 4849   Download: 135  Web of Science: 4  Crossref: 5
1772
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi
Clin Mol Hepatol. 2023;29(2):417-432.   Published online November 21, 2022
View: 7201   Download: 216  Web of Science: 4  Crossref: 6
Editorial
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clin Mol Hepatol. 2023;29(2):394-397.   Published online April 1, 2023
View: 4021   Download: 94  Web of Science: 2  Crossref: 1
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clin Mol Hepatol. 2023;29(2):390-393.   Published online March 20, 2023
View: 3811   Download: 68  Web of Science: 2  Crossref: 2
Original Article
1430
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang
Clin Mol Hepatol. 2019;25(1):52-64.   Published online October 23, 2018
View: 9928   Download: 361  Web of Science: 84  Crossref: 83
Review
NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
Stephen Caldwell
Clin Mol Hepatol. 2017;23(2):103-108.   Published online May 10, 2017
View: 13763   Download: 485  Web of Science: 35  Crossref: 34
Original Article
Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
Min-Sun Kwak, Donghee Kim, Goh Eun Chung, Seung Joo Kang, Min Jung Park, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee
Clin Mol Hepatol. 2012;18(4):383-390.   Published online December 21, 2012
View: 17747   Download: 134  Crossref: 90
5
Nonalcoholic Steatohepatitis
So-Young Jin
Clin Mol Hepatol. 2006;12(3):455-459.   Published online January 1, 2000
View: 2872   Download: 21
1 | 2 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 526
TOTAL : 2646077
Close layer